DJIA 17,959.44 154.64 0.87%
NASDAQ 4,781.42 16.04 0.34%
S&P 500 2,078.54 7.89 0.38%
market minute promo

Alnylam Pharmaceuticals (NASDAQ: ALNY)



company name or ticker

Alnylam Reveals Positive Data from its Pipeline Candidates - Analyst Blog

Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst

Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog

Alnylam Jumps on Positive Patisiran Data from Phase II Study - Analyst Blog

Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape

U.S. Stocks Fluctuate; Shutterfly Shares Decline On Aborted Merger Talks

U.S. Stocks Fluctuate; Shutterfly Shares Decline On Aborted Merger Talks

Midday Gainers From October 13 - Doral Financial, Nanosphere, Ibio, Atlas Energy

Why Alnylam Pharmaceuticals Surged Higher

1:20 p.m. EDT: Alnylam surges higher after an open-label midstage study reveals encouraging early efficacy for patisiran in patients with familial amyloidotic polyneuropathy.

Lithia Motors Dips On Lowered Earnings Forecast; CSX Shares Gain

Alnylam Pharmaceuticals (ALNY): Heavy Pre-Market Activity

See More Articles...